A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT06820463 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Telisotuzumab Adizutecan
DRUG: Fluorouracil
DRUG: Oxaliplatin
DRUG: Leucovorin
DRUG: Bevacizumab
DRUG: Panitumumab

Sponsor

AbbVie